Tetalin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tetalin

Property Description
Active Ingredient Atenolol (INN)
Form Oral tablet, intravenous solution
Pharmacological Class Cardioselective beta-blocker
Origin Synthetic compound

Tetalin is a pharmaceutical preparation containing the active ingredient Atenolol, which is classified as a cardioselective beta-blocker (beta-adrenergic receptor antagonist). This medication is a synthetic compound belonging to the sympatholytic class of drugs that modulates the function of the body's sympathetic nervous system. The established pharmacology of Atenolol is clinically recognized for its specific effects on heart tissue. While Tetalin is a trade name, the active substance Atenolol is also widely available under other brands or as a generic drug.


Atenolol is known as a second-generation beta1-selective agent, meaning its primary action is focused on the beta1 receptors highly concentrated in the cardiac muscle, distinguishing it from older, non-selective compounds. The drug is most commonly administered via the oral route as a tablet, though it is also available as an intravenous solution for acute clinical settings. As a hydrophilic compound, Atenolol exhibits low lipid solubility, a characteristic that influences its distribution within the body. It is available both as a single-entity product and combined with a diuretic in a fixed-dose combination.

General Purpose and Action of Cardioselective beta-Blockers

The general purpose of Tetalin is to provide cardiovascular modulation by reducing the stimulating effect of adrenaline and related hormones on the heart. This action is achieved through targeted receptor antagonism, where Atenolol occupies the beta1 receptors to dampen the signal. This mechanism results in a decrease in both the frequency and force of heart contractions, which in turn helps to lower systemic vascular pressure. By reducing the demands placed on the cardiac muscle, the drug assists in the reduction of the heart's workload.

Regulatory References

  1. Atenolol: MedlinePlus Drug Information

What side effects are possible with Tetalin?

Possible Side Effects and Safety Information

The safety profile of Tetalin (Atenolol) is formally structured in regulatory documents by classifying potential adverse reactions according to frequency and the body system affected. Understanding these classifications is key to appreciating the officially documented risks associated with the medicine.


Frequency-Classified Adverse Reactions

Adverse reactions are grouped based on the likelihood of their occurrence, as defined in official regulatory data:

  • Common: Events that may affect up to 1 in 10 people, including bradycardia (slow heart rate), fatigue, cold extremities, and general gastrointestinal disturbances.
  • Uncommon: Events that may affect up to 1 in 100 people, such as sleep disturbances and elevations of transaminase levels.
  • Rare: Events that may affect up to 1 in 1,000 people, including mood changes, confusion, paresthesia (tingling), dry eyes, and certain skin reactions.

System-Organ Classes and Serious Concerns

The officially listed effects fall into various System-Organ Classes, including Cardiac disorders, Vascular disorders, Nervous system disorders, and Psychiatric disorders. Regulatory documents specifically highlight the risk of serious adverse reactions, such as the precipitation of second or third-degree heart block, severe hypotension, and overt cardiac failure.

Population-Specific and Time-Related Safety

Official labels note specific safety considerations for certain patient groups. Individuals with impaired renal function require dosage adjustments due to how the medicine is cleared from the body. Caution is also noted for patients with diabetes, as the medicine may mask symptoms of hypoglycemia. Furthermore, the label specifies a serious risk of cardiac events if the treatment is abruptly discontinued, particularly in those with existing coronary artery disease.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Tetalin

Documented Overdose Presentations: Overdose may be characterized by cardiovascular signs including severe bradycardia (slow heart rate), profound hypotension (low blood pressure), sinus pause, and the precipitation of congestive heart failure. Documented non-cardiac manifestations include lethargy, a disorder of respiratory drive, wheezing, bronchospasm, and hypoglycemia. Acute massive overdose has been associated with profound cardiac depression.


When Immediate Medical Help is Required: Individuals must seek immediate medical attention when severe manifestations occur, including marked bradycardia, refractory hypotension, signs of congestive heart failure, or severe respiratory compromise. Overdose may result in severe hypotension or profound cardiac depression, necessitating urgent, specialized medical intervention.


Official Management and Supportive Measures: Treatment is directed to the removal of any unabsorbed drug, often utilizing procedures such as gastric lavage or administration of activated charcoal. Since no specific antidote is known, management is primarily symptomatic and supportive. The drug can be removed from the general circulation by hemodialysis, and in refractory cases, the use of a cardiac pacemaker may be necessary.


Population-Specific Overdose Notes: Neonates born to mothers receiving the drug near term may be at specific risk for bradycardia and hypoglycemia.


Connection to the overall overdose profile: The regulatory documents define the overdose profile by listing specific, severe manifestations that reflect an exaggerated physiological effect, primarily impacting the heart and circulation. The presence of these serious symptoms, such as congestive heart failure and severe hypotension, constitutes the regulator-mandated trigger for seeking urgent medical help. Furthermore, the required management procedures, including hemodialysis and pharmacological support, establish the necessity of hospital-level care for documented overdose scenarios.

Therapeutic Uses of Tetalin

What Tetalin Treats: Main Uses and Benefits

Tetalin is commonly used for the long-term management of conditions characterized by systemic imbalance and recurrent episodes. The medication assists with managing sustained high arterial pressure (hypertension), helping to manage the overall physiological strain. It is also applied in addressing symptomatic clusters of heightened activity, including angina pectoris (exertional chest discomfort) and certain rapid heart rhythms. Furthermore, it is considered relevant for maintaining stability after an acute myocardial infarction and for managing the occurrence of recurrent migraines.

The medication's primary role is to contribute to easing the overall symptom load associated with these conditions, supporting long-term vascular health. The use is generally applied in clinical settings that involve chronic or episodic symptom patterns, helping patients cope more steadily with difficult manifestations.

“The medication is used across domains where additional symptomatic support is needed, primarily to ease discomfort and support cardiovascular stability.”


Quick Fact: Supportive Management for Cardiac Strain

Tetalin supports the heart muscle and is commonly used to help with managing the strain on the vascular system in patients with hypertension or coronary disease.

Regulatory References

  1. Official FDA Label via DailyMed

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Tetalin (Atenolol)

The official regulatory documents establish strict cardiovascular criteria for who can use Tetalin, which contains the active ingredient Atenolol. Use is generally permitted for adult populations with approved indications, but is contraindicated in several groups due to significant risks.

Classification Population/Condition (Regulatory Wording)
Absolute Contraindications Cardiogenic shock; Overt cardiac failure; Second or third-degree heart block; Severe bradycardia (le 50 beats/minute); Severe bronchial asthma/COPD; Untreated phaeochromocytoma [1.1, 1.2, 4.5].
Not Recommended Pediatric population (safety and efficacy have not been established) [1.4, 2.1]. Pregnant women (associated with intra-uterine growth restriction) [2.4, 4.1]. Breastfeeding mothers (due to excretion into human milk) [2.1, 4.4].
Conditional Use (Caution) Patients with Impaired renal function require caution due to slower drug removal and potential accumulation [3.1, 3.2]. Patients with diabetes or first-degree heart block [1.2, 4.1].

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use the medicine by establishing a clear set of absolute contraindications, primarily centered on severe cardiac instability (e.g., shock, high-degree heart block, severe bradycardia). Eligibility is further constrained by specific populations where the safety profile is not documented (pediatric population) or where known risks are significant (pregnancy/lactation). Conditional use is mandated by renal function status and co-existing conditions like diabetes, which require caution and monitoring based on labeled regulatory instructions.

What should I know about interactions with other medicines?

The regulatory profile for Tetalin (Atenolol) is primarily defined by documented pharmacodynamic potentiation and administration sequencing requirements. Co-administration is formally contraindicated with intravenous (IV) formulations of Verapamil and Diltiazem, as well as with the NSAID derivative Floctafenine and the antipsychotic Sultopride.

A significant number of interactions are due to additive effects. Combining Tetalin with other Anti-arrhythmics or certain Calcium Channel Blockers carries a documented risk of hypotension and bradycardia. Similarly, co-use with Insulin or Oral Antidiabetic Drugs may intensify blood sugar lowering effects and can officially mask key symptoms of hypoglycemia. Furthermore, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are documented to decrease the hypotensive action of Tetalin.

Pharmacokinetic constraints mandate timing separation for certain substances. Tetalin must be administered at least two hours apart from Aluminum Hydroxide (an antacid) or multivitamin preparations to prevent interference with gastrointestinal absorption. A procedural constraint exists for patients taking Clonidine: Tetalin must be withdrawn several days prior to discontinuing Clonidine to prevent severe rebound hypertension. Special consideration is noted for patients with impaired renal function due to the drug's primary renal clearance, which carries a risk of accumulation and heightened interaction potential.

Mechanism of Action

Selective Blockade of Cardiac beta1 Receptors

Tetalin’s mechanism begins as a competitive antagonist that selectively blocks beta1-adrenergic receptors in the heart, preventing binding by stimulating hormones. This targeted antagonism reduces sympathetic signaling at the receptor site, initiating a cascade that slows cell firing and reduces contractile force.


Modulation of Intracellular Signaling Cascades

The blockade of the beta1 receptor inhibits the Gs-protein signaling pathway, resulting in a marked decrease in intracellular cyclic AMP ( cAMP) levels. This molecular change limits the subsequent influx of calcium ions ( Ca^2+) into the cardiac cells. This modification of the second messenger system results in negative chronotropic (slowing rate) and negative inotropic (reducing force) effects.


️ Suppression of the Renal Hormone Pathway

The mechanism extends beyond the heart to target beta1 receptors on the juxtaglomerular cells in the kidneys. By blocking these receptors, Atenolol suppresses the release of renin, the initiating enzyme of the Renin-Angiotensin-Aldosterone System (RAAS). This action contributes to the modulation of systemic vascular tone and pressure.


Constraints of Dose and Structure

The drug is structurally hydrophilic (low lipophilicity), resulting in limited penetration across the blood-brain barrier (BBB), restricting its activity primarily to the periphery. Furthermore, the drug's beta1 selectivity is dose-dependent; at high concentrations, its mechanism extends to block beta2 receptors, losing its functional selectivity.

Dosage and Administration Information

The administration of Tetalin (Atenolol) is characterized by specific routes of delivery and corresponding dosing regimens. The medication is primarily available for oral use as immediate-release tablets in strengths of 25 mg, 50 mg, and 100 mg, but an intravenous solution is also available for specific acute clinical scenarios.

The standard oral dosing pattern for chronic use is generally once daily, with the instruction that the dose be taken around the same time each day, and it may be taken with or without food. For sustained high arterial pressure or angina, the initial oral dose is typically 50 mg once daily, with the maintenance dose ranging from 50 mg to 100 mg daily. The dose may be adjusted after one to two weeks if necessary, though doses above 100 mg for sustained high pressure are not generally associated with additional benefit.

Intravenous administration is reserved for initial management during the acute phase of a cardiac event, involving an injection of 5 mg followed by a second 5 mg injection 10 minutes later. This immediate treatment is then succeeded by an oral 50 mg dose 12 hours after the final IV dose, transitioning the patient to an established oral maintenance regimen. A missed oral dose should be taken as soon as remembered, unless it is close to the next scheduled dose, in which case the missed dose must be skipped.

Specific adjustments to the use pattern are required for certain populations. For older adults, a reduced starting dose, such as 25 mg once daily, is often advised. Since the medication is primarily eliminated by the kidneys, maximum oral doses are adjusted for patients with renal impairment. Furthermore, treatment cessation is performed by gradually reducing the daily dose over one to two weeks to manage the overall use protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tetalin (Atenolol)


Evidence for Use in Managing High Blood Pressure (Hypertension)

Research examining the use of Tetalin for high blood pressure involves randomized controlled trials (RCTs) and systematic reviews. These studies monitored outcomes related to systemic or functional imbalance, such as measurements of changes in systolic and diastolic blood pressure ( BP). Longer-term studies also monitored the occurrence of major cardiovascular events, such as stroke and heart attack, across observed populations.

Trials described measurements of BP changes observed in the studies compared to other agents used to manage hypertension. Research highlights data show patterns related to cardiovascular events in certain populations. However, when compared directly with newer antihypertensive agents, findings were mixed regarding the patterns observed for stroke outcomes.

Evidence for Use After an Acute Heart Attack (Post-Myocardial Infarction Stability)

Tetalin was studied for use in secondary prevention following an acute heart attack. Research examined outcomes linked to physiological strain or stress and survival outcomes (mortality rates). Early long-term trials reported data show patterns related to survival outcomes. More recent research describes patterns where the association was observed in patients with measurable impairment of the heart's pumping function.

What remains uncertain is the evidence for use in patients who have fully preserved heart function after modern revascularization procedures, as long-term effects are not fully established in this specific modern cohort. Evidence is limited for longitudinal outcomes based on trials reflecting practices from earlier decades.


Key Research Gaps and Uncertainties

Data for certain groups remain insufficient. Comparative evidence is lacking against some newer drug classes in specific contexts. Findings were mixed in some meta-analyses comparing Tetalin to newer antihypertensive agents in studies examining stroke outcomes. The research does not determine whether an individual will respond similarly to the group patterns observed, as evidence quality varies across studies, and long-term effects are not fully established in all current clinical contexts.

Frequently Asked Questions (FAQ)

Common questions about Tetalin (FAQ)

Q: Is it true that Tetalin can cause serious liver problems?

According to official product information, rare cases of drug-induced liver injury have been associated with this medicine. Mild-to-moderate elevations of liver enzymes (transaminase) may occur in a small number of patients (1% to 2%). These changes often do not cause symptoms.

Q: Is it normal to feel slightly nauseous when first starting Tetalin?

Gastrointestinal disturbances are listed in official safety information as a common side effect. Product literature suggests that taking the medicine after a meal or a snack may be helpful. This is based on management strategies related to feelings of sickness, such as nausea.

Q: Are there any specific vitamins or supplements that are known to interact with Tetalin?

Official documents note that multivitamin preparations containing minerals may decrease the effectiveness of Tetalin. To potentially avoid interference with drug absorption, a separation of at least two hours between taking Tetalin and these supplements is indicated in the official labeling.

Q: Can Tetalin be taken at the same time as my other prescription medications?

The product information lists several specific prescription medicines, particularly certain heart and blood pressure drugs, that are either strictly contraindicated or require timing separation from Tetalin. Combining this medicine with other blood pressure medicines may increase the risk of excessively low blood pressure. Detailed information regarding interactions is found in the official label.

Q: Are there any dietary restrictions or foods to avoid when taking Tetalin?

The drug label includes information about potential dietary restrictions. It advises against consuming large amounts of orange juice, as this may decrease the medicine's effectiveness. The official guidance indicates that multivitamin preparations containing minerals be taken at least two hours apart from Tetalin.

Q: What is the risk of having an allergic reaction to Tetalin?

Official safety documents do not explicitly list a general 'allergic reaction,' but they do note 'skin reactions' as a rare potential adverse event. For severe symptoms such as difficulty breathing, swelling, or severe skin changes, the official guidance emphasizes the importance of seeking emergency medical care.

Q: What should I know about the long-term safety profile of Tetalin?

The official long-term safety profile highlights the risk associated with abrupt discontinuation. Regulatory documents specify that stopping the medicine suddenly, especially for patients with existing heart disease, carries a serious risk of cardiac events. The label indicates that monitoring for common side effects like bradycardia (slow heart rate) is part of the established treatment protocol.

Q: How does the mechanism of Tetalin work in simple terms?

Tetalin works by selectively blocking specific receptors (known as beta1 receptors) that are highly concentrated in the heart. This action reduces the effect of stimulating hormones on the heart muscle. In simple terms, this slows the heart rate and reduces the force of heart contractions, which ultimately helps to lower the overall systemic blood pressure.

Q: Do I need to have regular blood tests while taking Tetalin?

Official documents do not explicitly mandate routine blood tests for all patients taking Tetalin. However, the label notes that the medicine can increase levels of certain laboratory values, such as liver enzymes and kidney function markers. The labeling specifies that monitoring is required for patients with impaired kidney function, due to the way the drug is eliminated.

Q: What did the studies say about how effective Tetalin is compared to a placebo?

Clinical trials indicate that Tetalin is effective in reducing blood pressure and improving exercise tolerance for patients with angina. The medicine's effects begin to be apparent within one hour of taking an oral dose, demonstrating a clear physiological effect compared to no treatment.

Q: Does taking Tetalin require any change to my lifestyle or diet?

Yes. Official advice often accompanies treatment with recommendations for lifestyle adjustments to help manage the underlying condition. These generally include limiting or avoiding alcohol consumption, stopping smoking, reducing salt intake, and engaging in appropriate regular exercise.

Q: Can Tetalin cause problems with vision or hearing?

Blurred vision is reported as a common side effect, and dry eyes is listed as a rare side effect in the official safety profile. Issues specifically related to hearing problems are not commonly noted in the regulatory documents.

Q: What is the official indication for Tetalin?

According to official regulatory documents, Tetalin (Atenolol) is approved for three main uses: the treatment of high blood pressure (hypertension), the long-term management of chest pain (angina pectoris), and the management of hemodynamically stable patients after an acute heart attack (myocardial infarction).

Q: How quickly does Tetalin usually start to show an effect?

A significant physiological effect is apparent within one hour after taking a single oral dose. This effect typically reaches its maximum benefit within 2 to 4 hours. For acute situations, the effect of an intravenous dose is maximal within five minutes.

Q: How long does one dose of Tetalin typically stay active in the body?

Following standard oral doses, the blood pressure-lowering and receptor-blocking effects generally persist for at least 24 hours. The time it takes for half of the medicine to be eliminated (the half-life) is approximately six to seven hours.

Q: Is it safe to drink alcohol in moderation while taking Tetalin?

Official documents state that alcohol can increase the blood pressure-lowering effects of Tetalin. This additive effect may cause symptoms such as dizziness, lightheadedness, or fainting. General guidance suggests limiting or avoiding alcohol, particularly when treatment is initiated.

Q: Does Tetalin cause weight gain or weight loss?

Weight gain is a reported side effect, particularly for older beta-blockers like Tetalin. Official reports indicate the average weight gain is about 1.2 kg over the first few months of use.

Q: Does Tetalin affect a person's ability to drive or operate machinery?

Yes. Tetalin can cause side effects like dizziness, sleepiness, or lightheadedness, especially when treatment is initiated. The official warning states that activities requiring mental alertness, such as driving, cycling, or operating machinery, should be avoided until the individual knows how the medicine affects them.

Q: What is the official guidance on managing a common side effect like dry mouth from Tetalin?

Dry mouth is a reported side effect of the medicine. While official regulatory documents do not provide detailed guidance for managing dry mouth, the label notes that taking the medicine with food has been suggested as a strategy to help alleviate another common gastrointestinal side effect, nausea.

Q: Does Tetalin interact with grapefruit or grapefruit juice?

The medicine's official label does not specifically list a major interaction with grapefruit or grapefruit juice. However, because interactions are often not fully established in regulatory data, caution is generally suggested regarding mixing unlisted herbal remedies and supplements with heart medications.

Q: Can Tetalin be taken with herbal remedies like St. John's Wort?

Official health guidance indicates that caution is appropriate regarding mixing Tetalin with unlisted herbal remedies and supplements. Since these products are not subject to the same testing as prescription medicines, their potential effect on the drug’s efficacy and safety profile may not be fully established.

How should Tetalin be stored and disposed of?

How to Store and Dispose of Tetalin?

The official regulatory guidelines for Tetalin (Atenolol) mandate specific conditions for storage and disposal to maintain product integrity and ensure safety.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature, between 20 C and 25 C (68 F to 77 F).
Protection Keep in the original, tightly closed container and protect from moisture and excessive heat. Do not store in high-humidity areas, such as a bathroom.
Safety The medication must be kept out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Tetalin must be disposed of according to local pharmaceutical waste regulations. The safest method is to use an authorized community drug take-back program or collection site. Disposal via household wastewater, such as flushing down the toilet, is generally not recommended unless explicitly advised by official governmental guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tetalin found in:

A-Z Index: